Collaborata

Medical Cannabis: Implications for Prescription Drugs, Health Care and Consumer Goods

The Pitch

Illinois was the 20th state to establish a medical-marijuana program. The growing wave of legalization and normalization of cannabis usage has resulted in changing consumer attitudes and behaviors. Patients have begun to swap certain health-and-wellness products for medical marijuana. This trend is at its beginning and its impact on prescription drugs and countless items in the health-and-wellness aisles is only going to grow.

Within this study of a single medical cannabis market, you'll discover key need states that drive cannabis consumption and impact more than 130-million adults impacted by chronic-pain conditions.

This study of Illinois -- one of the most restrictive medical-cannabis states in the country -- illuminates usage trends with far-reaching implications across adjacent categories and services:

• OTC medications ($34 billion – 2016 retail sales - CHPA)
• Vitamin supplements ($27.6 billion – 2016 retail sales – Euromonitor)
• Prescription drugs ($424 billion – 2015 retail, mail & amp; non-retail sales – IMS Health)
• In-store pharmacy retailers ($208 billion – 2015 chain, independents & grocery store pharmacies – IMS)

Email info@collaborata.com to schedule a call with the research leaders. (Click link below to read National Pain Report article about this study: http://nationalpainreport.com/illinois-medical-cannabis-patient-study-shows-positive-impact-on-pain-8833677.html)

Purchase Price: $9,375.00
Purchase this project

Purpose

To offer fresh insights for key industries impacted by the growth of medical marijuana into the reasons why patients choose cannabis as an alternative or addition to other health-and-wellness products, through an analysis of data from one model state (Illinois).

Additional objectives
Project Details

Methodology

Qualitative/Quantitative

Aclara Research partnered with medical cannabis patient social-media groups to conduct this research. These groups focus on medical cannabis usage but also include adult use consumers .

We explored qualitative insights across key focus areas and invited members to respond. Topics included:

• Doctor and patient communication
• Commonly experienced symptoms
• Perceived product efficacy
• Retail experience and product selection

The Aclara team offers a webinar presentation to each subscriber of the study. In addition, clients may contact Aclara Research to present the study in person (Aclara will bill additionally for the presentation). .

Company: Aclara Research

Previous Projects: 1

Rating: Supplier has not been rated

Aclara Research is a team of consulting professionals linking cannabis patient and consumer insights with healthcare research to solve commercial challenges. Aclara insights illuminate market opportunities, product development, and business strategy through ongoing engagement with our research panel of cannabis patients and consumers across legal cannabis markets. Learn more about Aclara Research by clicking https://www.aclararesearch.com

Add Comment

Error: You must enter text in the box below.



The Pitch

Illinois was the 20th state to establish a medical-marijuana program. The growing wave of legalization and normalization of cannabis usage has resulted in changing consumer attitudes and behaviors. Patients have begun to swap certain health-and-wellness products for medical marijuana. This trend is at its beginning and its impact on prescription drugs and countless items in the health-and-wellness aisles is only going to grow.

Within this study of a single medical cannabis market, you'll discover key need states that drive cannabis consumption and impact more than 130-million adults impacted by chronic-pain conditions.

This study of Illinois -- one of the most restrictive medical-cannabis states in the country -- illuminates usage trends with far-reaching implications across adjacent categories and services:

• OTC medications ($34 billion – 2016 retail sales - CHPA)
• Vitamin supplements ($27.6 billion – 2016 retail sales – Euromonitor)
• Prescription drugs ($424 billion – 2015 retail, mail & amp; non-retail sales – IMS Health)
• In-store pharmacy retailers ($208 billion – 2015 chain, independents & grocery store pharmacies – IMS)

Email info@collaborata.com to schedule a call with the research leaders. (Click link below to read National Pain Report article about this study: http://nationalpainreport.com/illinois-medical-cannabis-patient-study-shows-positive-impact-on-pain-8833677.html)

Purchase Price: $9,375.00
Purchase this project